The canonical profile remains the primary reading view. Read the canonical profile.
We added the six Novo Nordisk Phase 3 trials that ClinicalTrials.gov lists under the name zenagamtide, which the previous version did not describe, from registry records PeptideScanner retained on November 15, 2026. 5678910
What this version reported
Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects. Phase 3 trials registered as zenagamtide have not reported results.↗↗↗↗↗↗↗↗↗
- Novo Nordisk A/S↗
Trial records: NCT06049329
Reader guide in this version
Key takeaway
Amycretin, now named zenagamtide, is an experimental Novo Nordisk peptide that activates the receptors for GLP-1 and amylin, two hormones involved in appetite and blood sugar.1,4 It is not FDA-approved. The sources reviewed here describe it only in clinical trials, and none reports an approval in any country.1,4,5,6,7,8,9,10 Published randomized trials report weight loss in early studies and lower blood sugar in a Phase 2 diabetes trial, with common gastrointestinal side effects. Each trial had fewer than 300 participants.2,3,4 Novo Nordisk has registered Phase 3 trials of zenagamtide in obesity, type 2 diabetes and cardiovascular disease on ClinicalTrials.gov. None had posted results when PeptideScanner retained the six records cited here.5,6,7,8,9,10
At a glance
- What it is
- An investigational single-molecule agonist of the GLP-1 and amylin receptors from Novo Nordisk. The 2026 Phase 2 report names it zenagamtide (formerly amycretin) and says it also acts on calcitonin receptors.1,4
- FDA status
- Not FDA-approved. The sources reviewed here describe it only in clinical trials sponsored by Novo Nordisk, including registered Phase 3 trials.1,4,5,6,7,8,9,10
- Human evidence
- Smaller randomized, placebo-controlled trials: two early trials in adults with overweight or obesity and a Phase 2 trial in type 2 diabetes. Registered Phase 3 trials have not reported results.2,3,4,5,6,7,8,9,10
- Evidence strength
- Smaller controlled human trials
What is amycretin?
Amycretin is an experimental drug being developed by Novo Nordisk, which ClinicalTrials.gov lists as the sponsor of the trial records cited on this profile.1,5,6,7,8,9,10
A 2026 Lancet report describes zenagamtide, formerly amycretin, as a single molecule that activates the receptors for GLP-1, amylin and calcitonin. Novo Nordisk’s Phase 3 trials are registered under the name zenagamtide.4,5,6,7,8,9,10
How is amycretin thought to work?
The published trial reports describe amycretin as a unimolecular GLP-1 and amylin receptor agonist, meaning one molecule designed to mimic two hormones that help regulate appetite and blood sugar.2,3
The sources reviewed here do not establish how much each receptor contributes to the effects reported in trials.2,4
What do human studies show?
A first-in-human randomized, placebo-controlled trial in 144 adults with overweight or obesity was designed mainly to assess safety. Adverse events were mild or moderate, and gastrointestinal events were common.2
In a randomized Phase 1b/2a trial in 125 adults with overweight or obesity lasting up to 36 weeks, estimated weight reductions were greater with amycretin than placebo; gastrointestinal events were common and many participants withdrew.3
In a 36-week randomized, placebo-controlled Phase 2 trial in 262 adults with type 2 diabetes, HbA1c, a measure of long-term blood sugar, improved more with the drug than with placebo. Gastrointestinal adverse events were common.4
These were short trials with mostly safety or blood-sugar outcomes, and they do not show long-term benefits or rare harms.2,3,4
The Phase 3 trials registered under the name zenagamtide had not reported results when PeptideScanner retained their ClinicalTrials.gov records: two were recruiting and four were not yet recruiting.5,6,7,8,9,10
What the evidence base contains
- Controlled human trial A first-in-human, double-blind, randomized, placebo-controlled Phase 1 trial in 144 adults with overweight or obesity, designed mainly to assess safety.2
- Controlled human trial A randomized, placebo-controlled Phase 1b/2a trial in 125 adults with overweight or obesity at one research center, lasting up to 36 weeks.3
- Controlled human trial A 36-week double-blind, randomized, placebo-controlled Phase 2 trial in which 262 adults with type 2 diabetes were randomized, published in The Lancet in 2026.4
- Registered trial without results Six randomized Phase 3 trials of zenagamtide sponsored by Novo Nordisk and registered on ClinicalTrials.gov, none with posted results.5,6,7,8,9,10
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is amycretin FDA-approved?
No. Amycretin remains in clinical trials. None of the sources reviewed here reports an approval of amycretin or zenagamtide in any country.1,4,5,6,7,8,9,10
A Novo Nordisk trial in Japanese men with obesity is listed on ClinicalTrials.gov as completed, in a record last updated on March 5, 2025.1
The 2026 Phase 2 report was published under the name zenagamtide and describes it as formerly amycretin.4
ClinicalTrials.gov lists Novo Nordisk Phase 3 trials of zenagamtide in weight management. AMAZE 9 and AMAZE 13 compare it with placebo for weight loss in adults with obesity or overweight, the second in Asia, and AMBIENCE compares it with placebo in about 8,500 people with cardiovascular disease and overweight or obesity, with major cardiovascular events as its main outcome.5,6,8
Three further Phase 3 trials in type 2 diabetes measure HbA1c: AMBITION 1 and AMBITION 2 compare zenagamtide with placebo, the second in people who also have chronic kidney disease, and AMBITION 7 compares it with insulin glargine in people at increased cardiovascular risk. The registry records were last updated between September 1 and November 12, 2026.7,9,10
Registering a trial does not show that a drug works or is safe.5,6,7,8,9,10
Timeline
- Results of the first two randomized amycretin trials are published in The Lancet.2,3
- ClinicalTrials.gov updates the record of a completed Novo Nordisk amycretin trial in Japanese men.1
- Results of a Phase 2 trial in type 2 diabetes are published under the name zenagamtide.4
- ClinicalTrials.gov first posts AMAZE 13, the earliest-registered of the Phase 3 zenagamtide trials cited here.5
- ClinicalTrials.gov first posts AMBITION 1 and AMBITION 2, Phase 3 zenagamtide trials in type 2 diabetes.9,10
What is still unknown?
Whether its effects on weight and blood sugar hold up in larger, longer trials: the published trials lasted up to 36 weeks and had fewer than 300 participants each.2,3,4
Its long-term safety and effects on outcomes such as heart disease, which the published trials did not measure.2,3,4
What the Phase 3 trials will find: ClinicalTrials.gov lists their estimated primary completion dates between 2028 and 2030.5,6,7,8,9,10
Sources for this version
- 1Oral Amycretin in Japanese Men With Obesity · record history version 6 · last update posted 2025-03-05 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial (2025) · PMID 40550229 ↗
The Lancet · Official source · Source checked November 14, 2026
- 3Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study (2025) · PMID 40550231 ↗
The Lancet · Official source · Source checked November 14, 2026
- 4Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (2026) · PMID 42532080 ↗
The Lancet · Official source · Source checked November 14, 2026
- 5ClinicalTrials.gov record NCT07668401 · retained source version 2026-08-24:5833a93b62ac59e564069a1fd4bf8cd19222029a0b3f7ce99899f59f22b177dc ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 6ClinicalTrials.gov record NCT07720271 · retained source version 2026-09-28:93ed8b5caeb775d7d6fbd3c0d4e0c5ce26698ea8c1ae70efd4b447411785d74d ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 7ClinicalTrials.gov record NCT07797335 · retained source version 2026-09-01:bc9e4b3246b2a07cc90834c13fa40cb6e95033b38aa14b8b29396518aff35b74 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 8ClinicalTrials.gov record NCT07861100 · retained source version 2026-10-06:c1032ee418d61646c75ff354e74a7285b9376c0eaeb82c0622036ec003177db0 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 9ClinicalTrials.gov record NCT07931495 · retained source version 2026-11-12:23a664ffa2bff21e8dd34305b3456a3ee5f65f216d24ab4d40b786451213bde4 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 10ClinicalTrials.gov record NCT07931547 · retained source version 2026-11-12:2d2f13db63aaf8b3fc36fdb710419bcd545343ee84a805e746017fc30430e350 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026